90725-50-1

Usage

Uses

Used in Pharmaceutical Research:
6-bromo-3-methyl-1,3-dihydroindol-2-one is used as a building block for the synthesis of various pharmaceutical compounds due to its unique structure and reactivity. Its potential applications in this industry include the development of new drugs and the modification of existing ones to improve their efficacy and safety.
Used in Agrochemical Industries:
6-bromo-3-methyl-1,3-dihydroindol-2-one is used as a key intermediate in the synthesis of agrochemicals, such as pesticides and herbicides. Its unique structure and reactivity allow for the development of novel and more effective agrochemicals, contributing to improved crop protection and yield.

InChI:InChI=1/C9H8BrNO/c1-5-7-3-2-6(10)4-8(7)11-9(5)12/h2-5H,1H3,(H,11,12)

Upstream product

• 65617-24-5 2,6-dibromo-3-methyl-indole 
• 1202764-94-0 methyl 6-bromo-3-methyl-2-oxoindoline-3-carboxylate 
• 3460-18-2 1,4-dibromo-2-nitrobenzene 
• 609-08-5 Diethyl methylmalonate 
• 100487-81-8 2-(4-bromo-2-nitro-phenyl)malonic acid dimethyl ester 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 1202764-93-9 dimethyl 2-(4-bromo-2-nitrophenyl)-2-methylmalonate 
• 400620-76-0 2-(4-Bromo-2-nitro-phenyl)propionic Acid 
• 83-34-1 3-Methylindole 

Downstream Products

• 158326-84-2 6-Bromo-3,3-dimethyl-2-oxo-indole 
• 158326-85-3 6-Bromo-3,3-dimethyl-dihydroindole 

Relevant academic research and scientific papers

PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.

ALKYNYL ALCOHOLS AS KINASE INHIBITORS

Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

Heterocyclic sulfonamide derivatives

The present invention provides certain heterocyclic sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

Cardioselective antiischemic ATP-sensitive potassium channel openers. 4. Structure-activity studies on benzopyranylcyanoguanidines: Replacement of the benzopyran portion

The results of our efforts aimed at the replacement of the benzopyran ring of the lead cardiac selective antiischemic ATP-sensitive potassium channel (K(ATP)) opener (4) are described. Systematic modification of the benzopyran ring of 4 resulted in the discovery of a structurally simpler acyclic analog (8) with slightly lower antiischemic potency than the lead compound 4. Further structure-activity studies on the acyclic analog 8 provided the 2- phenoxy-3-pyridylurea analog 18 with improved antiischemic potency and selectivity compared to the benzopyran-based compound 4. These data demonstrate that the benzopyran ring of 4 and its congeners is not mandatory for antiischemic activity and cardiac selectivity. The results described in this paper also show that, as for the benzopyran class of compounds, the structure-activity relationships for the antiischemic and vasorelaxant activities of K(ATP) openers are distinct. The mechanism of action of the acyclic analogs (e.g., 18) still appears to involve K(ATP) opening as their cardioprotective effects are abolished by pretreatment with the K(ATP) blocker glyburide.